Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00516607
Other study ID # EORTC-26054
Secondary ID EORTC-26054
Status Active, not recruiting
Phase Phase 1
First received August 14, 2007
Last updated February 9, 2015
Start date July 2007

Study information

Verified date February 2015
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving enzastaurin together with temozolomide may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin when given together with temozolomide in treating patients with primary gliomas.


Description:

OBJECTIVES:

- To assess if full doses of enzastaurin hydrochloride and temozolomide can be used in combination for the treatment of patients with primary gliomas.

- To determine the recommended phase II dose.

OUTLINE: This is a multicenter study.

Patients receive oral enzastaurin hydrochloride once or twice daily on days 1-28* and oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

NOTE: *During the first course only, patients also receive enzastaurin hydrochloride on day -1.

Patients undergo blood sample collection on day 22 of course 1 and on day 5 of course 2 for pharmacokinetic studies of enzastaurin hydrochloride.

After completion of study treatment, patients are followed within 30 days and then every 3 months thereafter.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 28
Est. completion date
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed primary supratentorial glioma

- WHO histologic grade 3 or 4

- Patients who have undergone prior treatment for low-grade glioma that has transformed to glioblastoma (biopsy proven) allowed

- Amenable to standard temozolomide treatment

- First or second recurrent disease after prior surgery and/or radiotherapy OR newly diagnosed disease that is not amenable to radiotherapy (e.g., multifocal disease)

PATIENT CHARACTERISTICS:

- ECOG or WHO performance status 0-2

- Hemoglobin = 10.0 g/dL

- Neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Bilirubin = 1.5 x upper limit of normal (ULN)

- Alkaline phosphatase and transaminases = 2.5 x ULN

- Serum creatinine < 1.7 mg/dL

- Not pregnant or lactating

- Negative pregnancy test

- Fertile patients must use effective contraception

- Clinically normal cardiac function

- No ischemic heart disease within the past 6 months

- No clinically significant abnormalities or uncontrolled cardiac arrhythmia by ECG

- QTc interval = 450 msec (males) or = 470 msec (females) by baseline 12-lead ECG

- No history of congenital long QTc syndrome

- No history of stroke

- No other prior or concurrent malignancy within the past 5 years except cone biopsied carcinoma of the cervix or adequately treated basal or squamous cell skin carcinoma

- No unstable systemic diseases

- No active uncontrolled infections

- No uncontrolled hypertension

- No psychological, familial, sociological, or geographical condition that would preclude study participation

- Must be able to swallow tablets

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No more than 1 prior chemotherapy regimen in the adjuvant setting or for first recurrence

- Prior temozolomide allowed provided there was no disease progression during temozolomide treatment or within 6 weeks of completing temozolomide treatment

- Prior surgery for primary brain tumor within the past 3 months allowed

- Patients who are receiving corticosteroid treatment must be on a stable or decreasing dose for at least 1 week before study entry

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)

- At least 14 days since prior and no concurrent enzyme-inducing antiepileptic drugs including, but not limited to, any of the following:

- Phenytoin

- Carbamazepine

- Phenobarbital

- More than 30 days since prior and no other concurrent investigational treatments

- No concurrent anticoagulant treatment (e.g., warfarin)

- Low molecular weight heparin for patients who require anticoagulant therapy after starting study treatment may be allowed

- No concurrent routine use of colony-stimulating factors

- No other concurrent anticancer agents

Study Design

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
enzastaurin hydrochloride

temozolomide

Other:
pharmacological study


Locations

Country Name City State
United Kingdom Beatson West of Scotland Cancer Centre Glasgow Scotland

Sponsors (1)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Rampling R, Sanson M, Gorlia T, Lacombe D, Lai C, Gharib M, Taal W, Stoffregen C, Decker R, van den Bent MJ. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro Oncol. 2012 Mar;14(3):344-50. doi: — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Recommended phase II dose Yes
Primary Dose-limiting toxicity Yes
Secondary Response rate No
Secondary Progression-free survival No
Secondary Overall survival No
Secondary Pharmacokinetics of enzastaurin hydrochloride alone and in combination with temozolomide No
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003484 - Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Phase 1